Pliant Therapeutics Inc - Asset Resilience Ratio
Pliant Therapeutics Inc (PLRX) has an Asset Resilience Ratio of 73.40% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pliant Therapeutics Inc's Asset Resilience Ratio has changed over time. Check PLRX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pliant Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PLRX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $148.70 Million | 73.4% |
| Total Liquid Assets | $148.70 Million | 73.40% |
Asset Resilience Insights
- Very High Liquidity: Pliant Therapeutics Inc maintains exceptional liquid asset reserves at 73.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pliant Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Pliant Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Pliant Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pliant Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.60% | $145.50 Million | $225.23 Million | -7.08pp |
| 2024-12-31 | 71.68% | $284.54 Million | $396.95 Million | -12.48pp |
| 2023-12-31 | 84.16% | $431.01 Million | $512.15 Million | -0.70pp |
| 2022-12-31 | 84.85% | $297.50 Million | $350.61 Million | +17.53pp |
| 2021-12-31 | 67.32% | $148.93 Million | $221.22 Million | -9.15pp |
| 2020-12-31 | 76.48% | $226.01 Million | $295.53 Million | +62.23pp |
| 2019-12-31 | 14.25% | $16.97 Million | $119.06 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $66.53 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more